Info

🌱 來自: treatment of acute lymphoblastic leukemia (ALL)

post-remission therapy of treatment of acute lymphoblastic leukemia (ALL)

 (choice depends on risk of recurrence)

1. Average risk 💚

• consolidation/intensification chemo (~7 mo)
• → maintenance (~2–3 y)

2. High risk 🔴

• high-dose chemo w/ allo-HSCT considered for Pts in CR1.
• High-risk disease:
  • Ph ⊕
  • Ph-like
    • (based on gene expression)
  • MLL translocation
    • t(4;11)
  • complex karyotype
  • hypodiploid
    • (<44 chromosomes)
  • early T-cell phenotype
    • (ETP; lacks CD1a, CD8, CD5weak, myeloid markers)
  • minimal residual disease (MRD)
    • morphologic remission
    • but flow cytometry or molec. markers of tumor still detectable.